Loading
A phase 2 trial of Odronextamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies is a phase 2 interventional study registered as NCT03888105 by Regeneron Pharmaceuticals, with 515 participants enrolled, started 2019-11-13 and due to reach its primary completion in 2026-06-17. Interventions recorded: Odronextamab. Conditions listed: B-cell Non-Hodgkin Lymphoma (B-NHL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Hodgkin lymphoma.
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Follicular lymphoma.
Shares Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma, Odronextamab, CD3, CD20.
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific).
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Follicular lymphoma.
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Follicular lymphoma.
Shares Odronextamab, Regeneron, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/